NDV Vector Vaccine With Prefusion Spike for COVID-19 Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines against COVID-19 based on viral vectors like NDV are not effective due to pre-existing immunity in adults, and the SARS-CoV-2 spike glycoprotein S has significant structural differences that complicate recombinant vaccine stability and immunogenicity, making it difficult to produce on an industrial scale.
Innovation Solution
A recombinant paramyxovirus viral vector, such as Newcastle disease virus (NDV), is used with an exogenous nucleotide sequence encoding the SARS-CoV-2 spike glycoprotein S, stabilized in its prefusion form, to generate a cellular immune response, and is formulated with adjuvants for enhanced immunogenicity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human adenovirus or vaccinia virus vectors are used for COVID-19 vaccination, then vaccine delivery to human cells is achieved, but pre-existing immunity to these vectors reduces immunogenicity and effectiveness
Solution Approach 1:
The patent uses Newcastle disease virus (NDV) as an intermediary viral vector that is antigenically distinct from common human pathogens. NDV serves as a mediator to deliver the SARS-CoV-2 spike glycoprotein S antigen without triggering pre-existing immunity, thereby resolving the contradiction between vaccine delivery and immunogenicity reduction caused by pre-existing vector immunity
2Productivity
If SARS-CoV-2 spike glycoprotein S is produced recombinantly, then antigen production is achieved, but the protein is difficult to stabilize and replicate on industrial scale
Solution Approach 1:
The patent employs Newcastle disease virus as a biological intermediary system that naturally stabilizes and produces the SARS-CoV-2 spike glycoprotein S in a replicating viral context. This viral vector system enables industrial-scale production while maintaining protein stability, overcoming the limitations of conventional recombinant production methods
3Reliability
If containment measures are adopted to control COVID-19 spread, then pandemic control is achieved, but economic impact is dramatically increased
Solution Approach 1:
The patent implements preliminary protective action through vaccination before pandemic control measures are needed. By providing pre-established immune protection through the NDV-based vaccine, society can avoid or reduce the severity of containment measures, thereby protecting economic productivity while maintaining pandemic control
Data Source
AI summary
An active or inactivated recombinant vaccine against COVID-19 is described that comprises a Newcastle disease viral vector and a pharmaceutically acceptable carrier, adjuvant and/or excipient, characterized in that the viral vector is a virus capable of generating a cellular immune response that has a SARS-COV-2 exogenous nucleotide sequence inserted.